TY  - JOUR
AU  - Neu, Maria
AU  - Wöhrl, Carolin Michaela
AU  - Walter, Renate
AU  - Balagiannis, Nikolaos
AU  - Poettgen, Christoph
AU  - Käsmann, Lukas
AU  - Stuschke, Martin
AU  - Dannecker, Christian
AU  - Stüben, Georg
AU  - Kahl, Klaus-Henning
TI  - Multimodal chemoradiotherapy including interstitial brachytherapy enhances outcomes in FIGO stage IVA cervical cancer: a focus on tumor control and quality of life.
JO  - Strahlentherapie und Onkologie
VL  - 201
IS  - 10
SN  - 0179-7158
CY  - Heidelberg
PB  - Springer Medizin
M1  - DKFZ-2025-01052
SP  - 1018-1030
PY  - 2025
N1  - 2025 Oct;201(10):1018-1030
AB  - This study was performed to evaluate the outcomes of advanced radiotherapy techniques, including image-guided adaptive brachytherapy (IGABT), in International Federation of Gynecology and Obstetrics (FIGO) stage IVA cervical cancer patients with adjacent organ infiltration. A further aim was to identify prognostic factors influencing overall survival (OS) and local control (LC) in these patients, with a particular focus on toxicity and patient-reported outcomes (PROs).This retrospective, single-center study included 31 patients with FIGO stage IVA cervical cancer treated with definitive chemoradiotherapy between 2010 and 2020. All 31 patients underwent external-beam radiotherapy (EBRT), with concurrent cisplatin-based chemotherapy (CTX) administered in 25 cases and additional high-dose-rate brachytherapy (BT) performed in 24 cases. Treatment-related adverse events were categorized in accordance with the Common Terminology Criteria for Adverse Events (CTCAE; version 5.0) [1]. PROs were evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire version 3.0 (EORTC QLQ-C30), while sexual function was assessed through three specific questions adapted from the EORTC QLQ-BR23 module.Median OS was estimated at 51.7 months, with 2‑ and 5‑year OS rates of 58.1 and 46.2
KW  - Bladder or rectal infiltration (Other)
KW  - High-dose-rate brachytherapy (Other)
KW  - Image-guided radiotherapy (Other)
KW  - Locally advanced cervical cancer (Other)
KW  - Patient-reported outcome measures (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:40399493
DO  - DOI:10.1007/s00066-025-02407-x
UR  - https://inrepo02.dkfz.de/record/301515
ER  -